Novel Form of Acquired Long QT Syndrome

• Status: Recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to determine whether anti-Ro/SSA antibodies are associated with acquired QT prolongation in subjects with connective tissue disease. The investigators will investigate whether gender or race influence correlation between anti-Ro antibody status and prolonged QT interval and the role of inflammatory cytokines in association with anti-Ro antibodies and QT prolongation. The investigators propose to add an additional objective to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Narrows Institute for Biomedical Research
• Collaborator: VA New York Harbor Healthcare System
• Treatments: Prednisone

Criteria

Inclusion Criteria:

• Patients enrolled in New York Harbor Healthcare System with connective tissue disease

Exclusion Criteria:

• Atrial fibrillation

• Intraventricular conduction delay with wide QRS complex

• Acute medical conditions

• Drug overdose

• Hypothermia

• Known diagnosis or family history of hereditary Long QT syndrome, complete bundle brunch block, ventricular paced rhythm, profound bradycardia and tachycardia, and uncorrected hypothyroidism